+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8-year follow-up data of 281 patients from the international RIT-registry



Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8-year follow-up data of 281 patients from the international RIT-registry



Hematological Oncology 35: 361-362




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065040342

Download citation: RISBibTeXText

DOI: 10.1002/hon.2439_116


Related references

Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry. British Journal of Haematology 184(6): 949-956, 2019

Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. European Journal of Haematology 76(1): 58-63, 2005

Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. European Journal of Nuclear Medicine and Molecular Imaging 41(8): 1585-1592, 2014

Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network. Journal of Nuclear Medicine 52(9): 1354-1360, 2011

Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematologica 122(4): 193-199, 2009

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. Journal of Clinical Oncology 31(3): 308-313, 2013

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. Chinese Medical Journal 131(15): 1767-1775, 2018

Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leukemia and Lymphoma 55(1): 51-55, 2014

Consolidation with 90 Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. Leukemia and Lymphoma 60(11): 2689-2696, 2019

The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5): 1504-1508, 2006

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. British Journal of Haematology 173(2): 274-282, 2016

Durable Benefit Of Rituximab Maintenance Post-Autograft In Patients With Relapsed Follicular Lymphoma: 12-Year Follow-Up Of The Ebmt Lymphoma Working Party Lym1 Trial. Hematological Oncology 35: 32-33, 2017

Long-term follow-up of 2 patients treated with 90 Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. European Journal of Haematology 101(3): 415-417, 2018

Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica 98(10): 1571-1580, 2013

Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†. Annals of Oncology 27(6): 1088-1094, 2016